Zacks Investment Research upgraded shares of Ritter Pharmaceuticals Inc (NASDAQ:RTTR) from a sell rating to a hold rating in a research note published on Tuesday morning.

According to Zacks, “Ritter Pharmaceuticals, Inc. is involved in developing therapeutic products to treat inflammatory, gastrointestinal and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. Ritter Pharmaceuticals, Inc. is headquartered in Los Angeles, California. “

Separately, Maxim Group cut their price objective on shares of Ritter Pharmaceuticals from $7.00 to $6.00 and set a buy rating for the company in a research report on Monday, August 15th.

Shares of Ritter Pharmaceuticals (NASDAQ:RTTR) opened at 1.66 on Tuesday. Ritter Pharmaceuticals has a 52-week low of $0.98 and a 52-week high of $3.05. The stock’s 50 day moving average is $1.36 and its 200 day moving average is $1.49. The stock’s market capitalization is $14.25 million.

Ritter Pharmaceuticals (NASDAQ:RTTR) last posted its quarterly earnings data on Monday, August 8th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by $0.14. Equities research analysts expect that Ritter Pharmaceuticals will post ($1.38) earnings per share for the current fiscal year.

Ritter Pharmaceuticals Company Profile

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

5 Day Chart for NASDAQ:RTTR

Get a free copy of the Zacks research report on Ritter Pharmaceuticals (RTTR)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Ritter Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc and related companies with's FREE daily email newsletter.